This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cerus Corporation Reports Fourth Quarter And Year-End 2011 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and year ended December 31, 2011.

Fourth quarter 2011 results:

  • Total revenue of $10.4 million, a 61% increase from the fourth quarter of 2010;
  • Product revenue of $9.9 million, a 66% increase from the fourth quarter of 2010;
  • Operating expenses of $7.6 million compared to $7.4 million incurred during the fourth quarter of 2010.

Full Year 2011 results:

  • Total revenue of $33.0 million, a 43% increase from 2010;
  • Product revenue of $30.6 million, a 41% increase from 2010;
  • Operating expenses of $30.4 million compared to $27.0 million during 2010;
  • Cash of $25.8 million at December 31, 2011 compared to $30.0 million at December 31, 2010.

“2011 was our highest revenue year to date, driven by almost 40% growth in disposable kit demand year over year,” said William ‘Obi’ Greenman, president and chief executive officer of Cerus Corporation. “We expect product revenue will continue to grow in 2012, with anticipated product revenue in the range of $34 million to $36 million. This represents growth of approximately 11-18% in U.S. dollars, or 20-25% when comparing revenue in constant currency.”

Revenues

Total revenue for the fourth quarter of 2011 was $10.4 million, up from $6.5 million recognized during the fourth quarter of 2010. Product revenue was $9.9 million during the fourth quarter of 2011, representing an increase of $3.9 million, from $6.0 million recognized during the fourth quarter of 2010. The increase in product revenue during the fourth quarter of 2011 from the fourth quarter of 2010 was driven by a 49% increase in demand for INTERCEPT disposable kits and the December 2011 tender awarded to us for illumination devices in Russia. Government grant revenue in support for the development of the red blood cell system was $0.5 million during both the fourth quarters of 2011 and 2010.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,257.81 -27.93 -0.15%
S&P 500 2,130.22 -0.60 -0.03%
NASDAQ 5,101.8790 +11.0850 0.22%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs